Home
Storia in 1 fonti
Dupilumab shows benefits in infants with EoE not meeting approval thresholds
Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and growth improved after starting dupilumab, according to study results.In children with EoE, dupilumab (Dupixent; Regeneron, Sanofi) is FDA approved for use in those aged 1 to 11 years who weigh at least 15 kg.
Raccontata da
healio.com
Timeline cronologica
- ·
Q&A: Understanding the relationship between lymphoma, eczema and dupilumab
The dermatology community has long debated whether dupilumab treatment for atopic dermatitis is associated with the development of cutaneous T-cell lymphoma — a concern that…
- ·
Dupilumab shows benefits in infants with EoE not meeting approval thresholds
Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and growth improved after starting dupilumab, according…
- ·
Dupilumab therapy improves height, bone density for children with eczema
Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American…